179 related articles for article (PubMed ID: 9637481)
1. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway.
Bingisser RM; Tilbrook PA; Holt PG; Kees UR
J Immunol; 1998 Jun; 160(12):5729-34. PubMed ID: 9637481
[TBL] [Abstract][Full Text] [Related]
2. Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.
Kostecki KL; Iida M; Crossman BE; Salgia R; Harari PM; Bruce JY; Wheeler DL
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254801
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells in cancer and cancer therapy.
Lasser SA; Ozbay Kurt FG; Arkhypov I; Utikal J; Umansky V
Nat Rev Clin Oncol; 2024 Feb; 21(2):147-164. PubMed ID: 38191922
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Role of Mediterranean and Westernized Diets and Their Main Nutrients in the Modulation of Oxidative Stress in the Placenta: A Narrative Review.
García-Montero C; Fraile-Martinez O; De Leon-Oliva D; Boaru DL; Garcia-Puente LM; De León-Luis JA; Bravo C; Diaz-Pedrero R; Lopez-Gonzalez L; Álvarez-Mon M; García-Honduvilla N; Saez MA; Ortega MA
Antioxidants (Basel); 2023 Oct; 12(11):. PubMed ID: 38001771
[TBL] [Abstract][Full Text] [Related]
5. Suppressive myeloid cells in SARS-CoV-2 and
Shaw JA; Malherbe ST; Walzl G; du Plessis N
Front Immunol; 2023; 14():1222911. PubMed ID: 37545508
[TBL] [Abstract][Full Text] [Related]
6. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.
Li W; Pan X; Chen L; Cui H; Mo S; Pan Y; Shen Y; Shi M; Wu J; Luo F; Liu J; Li N
Front Immunol; 2023; 14():1186383. PubMed ID: 37342333
[TBL] [Abstract][Full Text] [Related]
7. Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine.
Ke CH; Chiu YH; Huang KC; Lin CS
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613591
[TBL] [Abstract][Full Text] [Related]
8. Immune Modulation by Myeloid-Derived Suppressor Cells in Diabetic Kidney Disease.
Hsieh CC; Chang CC; Hsu YC; Lin CL
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362050
[TBL] [Abstract][Full Text] [Related]
9. The function of myeloid-derived suppressor cells in COVID-19 lymphopenia.
Li T; Zheng F; Cheng F
Int Immunopharmacol; 2022 Nov; 112():109277. PubMed ID: 36206651
[TBL] [Abstract][Full Text] [Related]
10. Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.
Kim J; Thomas SN
Pharmacol Rev; 2022 Oct; 74(4):1146-1175. PubMed ID: 36180108
[TBL] [Abstract][Full Text] [Related]
11. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.
Kumar A; Taghi Khani A; Sanchez Ortiz A; Swaminathan S
Front Immunol; 2022; 13():901277. PubMed ID: 35865534
[TBL] [Abstract][Full Text] [Related]
12. Neutrophils: New Critical Regulators of Glioma.
Wang G; Wang J; Niu C; Zhao Y; Wu P
Front Immunol; 2022; 13():927233. PubMed ID: 35860278
[TBL] [Abstract][Full Text] [Related]
13. Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment.
Busà R; Bulati M; Badami E; Zito G; Maresca DC; Conaldi PG; Ercolano G; Ianaro A
Front Cell Dev Biol; 2022; 10():907572. PubMed ID: 35757002
[TBL] [Abstract][Full Text] [Related]
14. Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia.
Dong P; Chen L; Wu H; Huo J; Jiang Z; Shao Y; Ren X; Huang J; Li X; Wang M; Nie N; Zhang J; Jin P; Zheng Y; Ge M
Haematologica; 2022 Dec; 107(12):2834-2845. PubMed ID: 35734923
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-Derived Suppressor Cells in COVID-19: The Paradox of Good.
Grassi G; Notari S; Gili S; Bordoni V; Casetti R; Cimini E; Tartaglia E; Mariotti D; Agrati C; Sacchi A
Front Immunol; 2022; 13():842949. PubMed ID: 35572540
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Cell Therapeutics for Systemic Autoimmune Diseases.
Park Y; Kwok SK
Immune Netw; 2022 Feb; 22(1):e10. PubMed ID: 35291648
[TBL] [Abstract][Full Text] [Related]
17. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Joshi S; Sharabi A
Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression.
Cheng JN; Yuan YX; Zhu B; Jia Q
Front Cell Dev Biol; 2021; 9():740827. PubMed ID: 35004667
[TBL] [Abstract][Full Text] [Related]
19. Targeting Metabolic Pathways of Myeloid Cells Improves Cancer Immunotherapy.
Li J; Bolyard C; Xin G; Li Z
Front Cell Dev Biol; 2021; 9():747863. PubMed ID: 34988072
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the tumor immune microenvironment by metformin.
Wu Z; Zhang C; Najafi M
J Cell Commun Signal; 2022 Sep; 16(3):333-348. PubMed ID: 34611852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
